Research view
Switch to patient viewAcute myeloid leukaemia: trials that stopped early
Trials on Acute myeloid leukaemia that stopped early, each with the reason the sponsor wrote in the registry, quoted word for word. Next to them: finished trials whose registry record links a result paper.
Stopped early
167 stopped trials give a reason in the registry, latest registry update first. 4 more give no reason and are not listed.
Withdrawn
A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies
Reason given in the registry “insufficient staff and updates in standard practice have made it difficult to recruit participants”
Quoted unchanged from ClinicalTrials.gov; record updated 11 Dec 2023.
- Phase
- Phase 1/2
- Run by
- Naoyuki G. Saito, M.D., Ph.D.
- Registry record
- NCT05201183
Withdrawn
Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory Leukemias
Reason given in the registry “Investigator decision”
Quoted unchanged from ClinicalTrials.gov; record updated 4 Dec 2023.
- Phase
- Phase 1
- Run by
- Juan C. Ramos, MD
- Registry record
- NCT05321940
Suspended
Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid Leukemia
Reason given in the registry “Pause for changes in development strategies”
Quoted unchanged from ClinicalTrials.gov; record updated 23 Oct 2023.
- Ended
- Dec 2024
- Phase
- Phase 1/2
- Run by
- Innovent Biologics (Suzhou) Co. Ltd.
- Registry record
- NCT04485052
Withdrawn
Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients
Reason given in the registry “study postponed”
Quoted unchanged from ClinicalTrials.gov; record updated 20 Jul 2023.
- Ended
- Sept 2024
- Phase
- Phase 1/2
- Run by
- Actinium Pharmaceuticals
- Registry record
- NCT03932318
Withdrawn
Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML
Reason given in the registry “Following a recent cellular therapy strategy assessment, Amgen has decided to cancel study 20180091.”
Quoted unchanged from ClinicalTrials.gov; record updated 12 Jun 2023.
- Phase
- Phase 1
- Run by
- Amgen
- Registry record
- NCT03904069
Withdrawn
GM-CLAG in Relapsed/Refractory FLT3-mutated AML
Reason given in the registry “Sponsor withdrew funding”
Quoted unchanged from ClinicalTrials.gov; record updated 25 Apr 2023.
- Phase
- Phase 1
- Run by
- Ayman H Qasrawi
- Registry record
- NCT05330377
Withdrawn
Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML
Reason given in the registry “Principal investigator decided not to move forward with the study.”
Quoted unchanged from ClinicalTrials.gov; record updated 4 Apr 2023.
- Phase
- Phase 2
- Run by
- Washington University School of Medicine
- Registry record
- NCT04354025
Withdrawn
Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies
Reason given in the registry “The study is not initiated and we want it to be withdrawn.”
Quoted unchanged from ClinicalTrials.gov; record updated 1 Mar 2023.
- Phase
- Phase 1
- Run by
- Shanghai Pudong Hospital
- Registry record
- NCT05513612
Withdrawn
Diagnosis and Treatment of Periodontal Disease in Patients With AML
Reason given in the registry “PI left institution and research was cancelled due to his departure”
Quoted unchanged from ClinicalTrials.gov; record updated 22 Feb 2023.
- Run by
- Masonic Cancer Center, University of Minnesota
- Registry record
- NCT04530695
Withdrawn
Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RP7214 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia
Reason given in the registry “Change in development plan”
Quoted unchanged from ClinicalTrials.gov; record updated 31 Oct 2022.
- Ended
- Nov 2025
- Phase
- Phase 1/2
- Run by
- Rhizen Pharmaceuticals SA
- Registry record
- NCT05246384
Withdrawn
CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies
Reason given in the registry “Study was split into two new studies before the first participant was enrolled.”
Quoted unchanged from ClinicalTrials.gov; record updated 27 Sept 2022.
- Phase
- Phase 2
- Run by
- Baptist Health South Florida
- Registry record
- NCT04282174
Withdrawn
A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies
Reason given in the registry “Sponsor decision.”
Quoted unchanged from ClinicalTrials.gov; record updated 15 Jun 2022.
- Ended
- Jun 2025
- Phase
- Phase 1/2
- Run by
- Erasca, Inc.
- Registry record
- NCT05279859
Withdrawn
Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation
Reason given in the registry “Drug availability”
Quoted unchanged from ClinicalTrials.gov; record updated 9 Jun 2022.
- Ended
- Dec 2023
- Phase
- Phase 1
- Run by
- City of Hope Medical Center
- Registry record
- NCT04655391
Withdrawn
Daunorubicin or Idarubicin With Cytarabine Plus Quizartinib vs Physician's Choice in Newly Diagnosed FLT3-ITD+ AML
Reason given in the registry “Study turned out no longer feasible”
Quoted unchanged from ClinicalTrials.gov; record updated 25 May 2022.
- Ended
- Dec 2025
- Phase
- Phase 3
- Run by
- University Hospital Heidelberg
- Registry record
- NCT04676243
Withdrawn
Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS
Reason given in the registry “No funding support”
Quoted unchanged from ClinicalTrials.gov; record updated 11 Mar 2022.
- Ended
- Dec 2024
- Phase
- Phase 2
- Run by
- Washington University School of Medicine
- Registry record
- NCT04893915
Withdrawn
Study of APVO436 in Elderly or Unfit Patients With Newly Diagnosed AML
Reason given in the registry “Change of strategy”
Quoted unchanged from ClinicalTrials.gov; record updated 1 Dec 2021.
- Phase
- Phase 1
- Run by
- Aptevo Therapeutics
- Registry record
- NCT04973618
Withdrawn
HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation
Reason given in the registry “Medigene transfered all rights to a new Sponsor”
Quoted unchanged from ClinicalTrials.gov; record updated 8 Oct 2021.
- Ended
- Jul 2025
- Phase
- Phase 1
- Run by
- Medigene AG
- Registry record
- NCT04464889
Sources: ClinicalTrials.gov and the EU Clinical Trials Register. Status, reason, dates and result links are registry fields, shown as the registry gives them.